catumaxomab
Trade name: Removab
Catumaxomab, sold under the brand name Removab among others, is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany). — Wikipedia
Clinical trial activity
17 trials · 24 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2004 (NCT00189345)
Timeline
Indications
Studied for
Mechanism of action
- T cell surface glycoprotein CD3CROSS-LINKING AGENT
T cell surface glycoprotein CD3 cross-linking agent
Catumaxomab is a trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antingen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.
- Epithelial cell adhesion moleculeBINDING AGENT
EPCAM binding agent
CD3E activator
- Epithelial cell adhesion moleculeCROSS-LINKING AGENT
EPCAM cross-linking agent
Catumaxomab is a trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antingen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.
- T-cell surface glycoprotein CD3 epsilon chainCROSS-LINKING AGENT
CD3E cross-linking agent
- High affinity immunoglobulin gamma Fc receptor ICROSS-LINKING AGENT
FCGR1A cross-linking agent
- Low affinity immunoglobulin gamma Fc region receptor III-ACROSS-LINKING AGENT
FCGR3A cross-linking agent
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Multi-specific
- Yes
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaCatumaxomab ↗
- ChEMBLCHEMBL2108581 ↗
Also known as
- catumaxomab
- catumaxomab
- catumaxomab
- removab
- removab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04799847 | Phase 1/Phase 2 (Phase 2) | Jul 7, 2021 | LintonPharm Co.,Ltd. |
| NCT04819399 | Phase 1 | Jul 7, 2020 | Lindis Biotech GmbH, Urologische Klinik München-Planegg |
| NCT04222114 | Phase 3 | May 6, 2020 | LintonPharm Co.,Ltd. |
| NCT01815528 | Phase 2 | Mar 1, 2013 | Humboldt University |
| NCT01784900 | Phase 2 | Nov 1, 2012 | Institut Gustave Roussy |
| NCT01504256 | Phase 2 | Oct 1, 2011 | AIO-Studien-gGmbH, Neovii Biotech |
| NCT01320020 | Phase 1 | Feb 1, 2011 | Neovii Biotech, Universidad Autonoma de Barcelona, University of Copenhagen |
| NCT01246440 | Phase 2 | Jun 1, 2010 | Corporacion Parc Tauli, Grupo Español de Investigación en Cáncer de Ovario, Hospital Universitario Fundación Alcorcón, Hospital Universitari Son Dureta, Neovii Biotech, Universidad Autonoma de Barcelona, Universidad Autonoma de Madrid, Universidad Complutense de Madrid, University of Cantabria, University of Texas at Houston, University of Valencia, University of Zaragoza |
| NCT01065246 | Phase 2 | Nov 1, 2009 | Neovii Biotech |
| NCT00822809 | Phase 3 | Dec 1, 2008 | Neovii Biotech |
| NCT00563836 | Phase 2 | Nov 1, 2007 | Neovii Biotech |
| NCT00464893 | Phase 2 | Apr 1, 2007 | Neovii Biotech, University of Hamburg |
| NCT00377429 | Phase 2 | Sep 1, 2006 | Fresenius, Harvard University, Neovii Biotech |
| NCT00352833 | Phase 2 | Jul 1, 2006 | Neovii Biotech |
| NCT00326885 | Phase 2 | Jun 1, 2006 | Fresenius, Neovii Biotech, Stanford University |
| NCT00836654 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2004 | Neovii Biotech |
| NCT00189345 | Phase 2 | May 1, 2004 | AGO Germany |
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neovii Biotech | For profit | 11 | 9 | 3 | 2004 |
| Fresenius | For profit | 2 | 0 | 1 | 2006 |
| LintonPharm Co.,Ltd. | For profit | 2 | 2 | 2 | 2020 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 2 | 0 | 2 | 2010 |
| AGO Germany | Academic/Hospital | 1 | 1 | 1 | 2004 |
| AIO-Studien-gGmbH | For profit | 1 | 1 | 1 | 2011 |
| Corporacion Parc Tauli | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Grupo Español de Investigación en Cáncer de Ovario | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Hospital Universitario Fundación Alcorcón | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Hospital Universitari Son Dureta | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Humboldt University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Lindis Biotech GmbH | For profit | 1 | 1 | 1 | 2020 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Universidad Autonoma de Madrid | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Cantabria | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Hamburg | Academic/Hospital | 1 | 0 | 1 | 2007 |